Search Results - "Chretien, Marie‐Lorraine"

Adherence to immunomodulatory drugs in patients with multiple myeloma by Cransac, Amélie, Aho, Serge, Chretien, Marie-Lorraine, Giroud, Maurice, Caillot, Denis, Boulin, Mathieu

“…Immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide; IMID) are widely used in the treatment of multiple myeloma patients. To date, few data are…”
Get full text

Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma by Gueneau, Pauline, Chretien, Marie‐Lorraine, Cransac‐Miet, Amelie, Aho, Ludwig Serge, Lafon, Ingrid, Favennec, Camille, Guy, Julien, Caillot, Denis, Boulin, Mathieu

“…Objectives To investigate the efficacy, safety, and cost of a pomalidomide‐dexamethasone regimen in patients with relapsed and refractory multiple myeloma…”
Get full text

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study by Touzeau, Cyrille, Perrot, Aurore, Roussel, Murielle, Karlin, Lionel, Benboubker, Lotfi, Jacquet, Caroline, Mohty, Mohamad, Facon, Thierry, Manier, Salomon, Chretien, Marie-Lorraine, Tiab, Mourad, Hulin, Cyrille, Leleu, Xavier, Loiseau, Hervé Avet, Dejoie, Thomas, Planche, Lucie, Attal, Michel, Moreau, Philippe

Get full text

Self‐management of immunomodulatory drug treatment in multiple myeloma patients by Cransac, Amélie, Aho, Serge, Cosme, Edouard, Chretien, Marie‐Lorraine, Favennec, Camille, Schreder, Laure, Boutet, Mérédith, Gueneau, Pauline, Giroud, Maurice, Caillot, Denis, Boulin, Mathieu

“…Objective Immunomodulatory drugs (IMIDs: thalidomide, lenalidomide and pomalidomide) are widely used in patients with multiple myeloma (MM). The aim of our…”
Get full text

Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population‐based study in France by Atsou, Kueshivi Midodji, Rachet, Bernard, Cornet, Edouard, Chretien, Marie‐Lorraine, Rossi, Cédric, Remontet, Laurent, Roche, Laurent, Giorgi, Roch, Gauthier, Sophie, Girard, Stéphanie, Böckle, Johann, Wasse, Stéphane Kroudia, Rachou, Helene, Bouzid, Laila, Poncet, Jean‐Marc, Orazio, Sébastien, Monnereau, Alain, Troussard, Xavier, Mounier, Morgane, Maynadie, Marc

“…Background The excess mortality observed in Acute Myeloblastic Leukaemia (AML) patients, partly attributed to unequal access to curative treatments, could be…”
Get full text

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome by Roussel, Murielle, Lauwers-Cances, Valérie, Robillard, Nelly, Hulin, Cyrille, Leleu, Xavier, Benboubker, Lotfi, Marit, Gérald, Moreau, Philippe, Pegourie, Brigitte, Caillot, Denis, Fruchart, Christophe, Stoppa, Anne-Marie, Gentil, Catherine, Wuilleme, Soraya, Huynh, Anne, Hebraud, Benjamin, Corre, Jill, Chretien, Marie-Lorraine, Facon, Thierry, Avet-Loiseau, Hervé, Attal, Michel

“…The three-drug combination of lenalidomide, bortezomib, and dexamethasone (RVD) has shown significant efficacy in multiple myeloma (MM). The Intergroupe…”
Get full text

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial by Facon, Thierry, Dimopoulos, Meletios A., Meuleman, Nathalie, Belch, Andrew, Mohty, Mohamad, Chen, Wen-Ming, Kim, Kihyun, Zamagni, Elena, Rodriguez-Otero, Paula, Renwick, William, Rose, Christian, Tempescul, Adrian, Boyle, Eileen, Manier, Salomon, Attal, Michel, Moreau, Philippe, Macro, Margaret, Leleu, Xavier, Lorraine Chretien, Marie, Ludwig, Heinz, Guo, Shien, Sturniolo, Michael, Tinel, Antoine, Silvia Monzini, Mara, Costa, Bruno, Houck, Vanessa, Hulin, Cyrille, Yves Mary, Jean

“…Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of treatment. Patients from the large,…”
Get full text

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma by Touzeau, Cyrille, Perrot, Aurore, Hulin, Cyrille, Manier, Salomon, Macro, Margaret, Chretien, Marie-Lorraine, Karlin, Lionel, Escoffre, Martine, Jacquet, Caroline, Tiab, Mourad, Leleu, Xavier, Avet-Loiseau, Herve, Jobert, Alexandra, Planche, Lucie, Corre, Jill, Moreau, Philippe

“…•D-KRd induction and consolidation with double transplant is feasible in HR TE-NDMM.•D-KRd with double transplant result in high rates of MRD negativity, PFS,…”
Get full text

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma by Perrot, Aurore, Lauwers-Cances, Valérie, Tournay, Elodie, Hulin, Cyrille, Chretien, Marie-Lorraine, Royer, Bruno, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Fontan, Jean, Voillat, Laurent, Demarquette, Hélène, Collet, Philippe, Rodon, Philippe, Sohn, Claudine, Lifermann, François, Orsini-Piocelle, Frédérique, Richez, Valentine, Mohty, Mohamad, Macro, Margaret, Minvielle, Stéphane, Moreau, Philippe, Leleu, Xavier, Facon, Thierry, Attal, Michel, Avet-Loiseau, Hervé, Corre, Jill

“…The wide heterogeneity in multiple myeloma (MM) outcome is driven mainly by cytogenetic abnormalities. The current definition of high-risk profile is…”
Get full text

In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations by Lannes, Romain, Samur, Mehmet, Perrot, Aurore, Mazzotti, Celine, Divoux, Marion, Cazaubiel, Titouan, Leleu, Xavier, Schavgoulidze, Anaïs, Chretien, Marie-Lorraine, Manier, Salomon, Adiko, Didier, Orsini-Piocelle, Frederique, Lifermann, François, Brechignac, Sabine, Gastaud, Lauris, Bouscary, Didier, Macro, Margaret, Cleynen, Alice, Mohty, Mohamad, Munshi, Nikhil, Corre, Jill, Avet-Loiseau, Hervé

“…Multiple myeloma (MM) is characterized by copy number abnormalities (CNAs), some of which influence patient outcomes and are sometimes observed only at…”
Get full text

Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome by Baumelou, Marion, Payssot, Alexandre, Row, Celine, Racine, Jessica, Lafon, Ingrid, Bastie, Jean‐Noél, Chevreux, Steeve, Chrétien, Marie‐Lorraine, Maynadié, Marc, Caillot, Denis, Guy, Julien

Get full text

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor by Schavgoulidze, Anaïs, Talbot, Alexis, Perrot, Aurore, Cazaubiel, Titouan, Leleu, Xavier, Manier, Salomon, Buisson, Laure, Mahéo, Sabrina, Do Souto Ferreira, Laura, Pavageau, Luka, Hulin, Cyrille, Marolleau, Jean-Pierre, Voillat, Laurent, Belhadj, Karim, Divoux, Marion, Slama, Borhane, Brechignac, Sabine, Macro, Margaret, Stoppa, Anne-Marie, Sanhes, Laurence, Orsini-Piocelle, Frédérique, Fontan, Jean, Chretien, Marie-Lorraine, Demarquette, Hélène, Mohty, Mohamad, Avet-Loiseau, Hervé, Corre, Jill

“…•Del(1p32) is an independent and important adverse prognostic factor in myeloma.•Biallelic deletion of 1p32 dramatically worsens the prognosis compared with a…”
Get full text

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features by Cazaubiel, Titouan, Leleu, Xavier, Perrot, Aurore, Manier, Salomon, Buisson, Laure, Maheo, Sabrina, Do Souto Ferreira, Laura, Lannes, Romain, Pavageau, Luka, Hulin, Cyrille, Marolleau, Jean-Pierre, Voillat, Laurent, Belhadj, Karim, Divoux, Marion, Slama, Borhane, Brechignac, Sabine, Macro, Margaret, Stoppa, Anne-Marie, Sanhes, Laurence, Orsini-Piocelle, Frédérique, Fontan, Jean, Chretien, Marie-Lorraine, Demarquette, Hélène, Mohty, Mohamad, Schavgoulidze, Anais, Avet-Loiseau, Herve, Corre, Jill

“…Primary plasma cell leukemia (pPCL) is an aggressive form of multiple myeloma (MM) that has not benefited from recent therapeutic advances in the field…”
Get full text

Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO by Dumas, Pierre-Yves, Raffoux, Emmanuel, Bérard, Emilie, Bertoli, Sarah, Hospital, Marie-Anne, Heiblig, Maël, Desbrosses, Yohann, Bonmati, Caroline, Pautas, Cécile, Lambert, Juliette, Orvain, Corentin, Banos, Anne, Pasquier, Florence, Peterlin, Pierre, Marchand, Tony, Uzunov, Madalina, Frayfer, Jamilé, Turlure, Pascal, Cluzeau, Thomas, Jourdan, Eric, Himberlin, Chantal, Tavernier, Emmanuelle, Villate, Alban, Haiat, Stephanie, Chretien, Marie-Lorraine, Carre, Martin, Chantepie, Sylvain, Vaida, Ioana, Wemeau, Mathieu, Chebrek, Safia, Guillerm, Gaelle, Guièze, Romain, Debarri, Houria, Gehlkopf, Eve, Laribi, Kamel, Marcais, Ambroise, Santagostino, Alberto, Béné, Marie-Christine, Mineur, Ariane, Pigneux, Arnaud, Dombret, Hervé, Récher, Christian

“…The real-world efficacy and safety of gilteritinib was assessed in an ambispective study that included 167 R/R FLT3 -mutated AML patients. Among them, 140…”
Get full text

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association by Debarri, Houria, Lebon, Delphine, Roumier, Christophe, Cheok, Meyling, Marceau-Renaut, Alice, Nibourel, Olivier, Geffroy, Sandrine, Helevaut, Nathalie, Rousselot, Philippe, Gruson, Bérengère, Gardin, Claude, Chretien, Marie-Lorraine, Sebda, Shéhérazade, Figeac, Martin, Berthon, Céline, Quesnel, Bruno, Boissel, Nicolas, Castaigne, Sylvie, Dombret, Hervé, Renneville, Aline, Preudhomme, Claude

“…Acute myeloid leukemia (AML) is a heterogeneous disease. Even within the same NPM1-mutated genetic subgroup, some patients harbor additional mutations in FLT3,…”
Get full text

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience by Hebraud, Benjamin, Magrangeas, Florence, Cleynen, Alice, Lauwers-Cances, Valerie, Chretien, Marie-Lorraine, Hulin, Cyrille, Leleu, Xavier, Yon, Edwige, Marit, Gerald, Karlin, Lionel, Roussel, Murielle, Stoppa, Anne-Marie, Belhadj, Karim, Voillat, Laurent, Garderet, Laurent, Macro, Margaret, Caillot, Denis, Mohty, Mohamad, Facon, Thierry, Moreau, Philippe, Attal, Michel, Munshi, Nikhil, Corre, Jill, Minvielle, Stephane, Avet-Loiseau, Herve

“…In multiple myeloma, cytogenetic changes are important predictors of patient outcome. In this setting, the most important changes are deletion 17p, del(17p),…”
Get full text

Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study by Garderet, Laurent, Beohou, Eric, Caillot, Denis, Stoppa, Anne Marie, Touzeau, Cyrille, Chretien, Marie Lorraine, Karlin, Lionel, Moreau, Philippe, Fontan, Jean, Blaise, Didier, Polge, Emmanuelle, Gueye, Mor Seny, Ikhlef, Souhila, Marjanovic, Zora, Labopin, Myriam, Mohty, Mohamad

“…The feasibility and efficacy of high-dose melphalan followed by autologous hematopoietic stem cell transplantation in newly diagnosed elderly patients with…”
Get full text

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study by Heiblig, Maël, Rea, Delphine, Chrétien, Marie-Lorraine, Charbonnier, Aude, Rousselot, Philippe, Coiteux, Valérie, Escoffre-Barbe, Martine, Dubruille, Viviane, Huguet, Françoise, Cayssials, Emilie, Hermet, Eric, Guerci-Bresler, Agnès, Amé, Shanti, Sackmann-Sala, Lucila, Roy, Lydia, Sobh, Mohamad, Morisset, Stéphane, Etienne, Gabriel, Nicolini, Franck E.

“…•We report the use of ponatinib in chronic myelogenous leukemia (CML) patients who failed at least two lines of tyrosine kinase inhibitors (TKI) in a real-life…”
Get full text

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial by Boyle, Eileen M., Leleu, Xavier, Petillon, Marie‐Odile, Karlin, Lionel, Doyen, Chantal, Demarquette, Hélène, Royer, Bruno, Macro, Margaret, Moreau, Philippe, Fostier, Karel, Marie‐Lorraine, Chretien, Zarnitsky, Charles, Perrot, Aurore, Herbaux, Charles, Poulain, Stephanie, Manier, Salomon, Beauvais, David, Walker, Brian A., Wardell, Christopher P., Vincent, Laure, Frenzel, Laurent, Caillon, Hélène, Susanna, Schraen, Dejoie, Thomas, Avet‐Loiseau, Hervé, Mohty, Mohamad, Facon, Thierry, Arnulf, Bertrand, Dib, Mamoun, Brechignac‐Bureau, Sabine, Godmer, Pascal, Tempescul, Adrian, Fohrer, Cecile, Benboubker, Lotfi, Voillat, Laurent, Malfuson, Jean Valère, Mariette, Clara, Tiab, Mourad, Rigaudeau, Sophie, Jaccard, Arnaud, Stoppa, Anne‐Marie, Eisenmann, Jean‐Claude, Rodon, Philippe, Kolb, Brigitte, Decaux, Olivier, Onraed, Brigitte, Attal, Michel, Hulin, Cyrille

“…Summary Single agent daratumumab has shown clinical activity in relapsed, refractory multiple myeloma (RRMM). The Intergroupe Francophone du Myélome 2014‐04…”
Get full text

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma by Dejoie, Thomas, Corre, Jill, Caillon, Helene, Hulin, Cyrille, Perrot, Aurore, Caillot, Denis, Boyle, Eileen, Chretien, Marie-Lorraine, Fontan, Jean, Belhadj, Karim, Brechignac, Sabine, Decaux, Olivier, Voillat, Laurent, Rodon, Philippe, Fitoussi, Olivier, Araujo, Carla, Benboubker, Lotfi, Fontan, Charlotte, Tiab, Mourad, Godmer, Pascal, Luycx, Odile, Allangba, Olivier, Pignon, Jean-Michel, Fuzibet, Jean-Gabriel, Legros, Laurence, Stoppa, Anne Marie, Dib, Mamoun, Pegourie, Brigitte, Orsini-Piocelle, Frederique, Karlin, Lionel, Arnulf, Bertrand, Roussel, Murielle, Garderet, Laurent, Mohty, Mohamad, Meuleman, Nathalie, Doyen, Chantal, Lenain, Pascal, Macro, Margaret, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Herve

“…Guidelines for monitoring multiple myeloma (MM) patients expressing light chains only (light-chain MM [LCMM]) rely on measurements of monoclonal protein in…”
Get full text